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Abstract: Following major advances in the field of medicinal chemistry, novel drugs can 
now be designed systematically, instead of relying on old trial and error approaches. 
Current drug design strategies can be classified as being either ligand- or structure-based 
depending on the design process. In this paper, by describing the search for an ATP 
synthase inhibitor, we review two frequently used approaches in ligand-based drug design: 
The pharmacophore model and the quantitative structure-activity relationship (QSAR) 
method. Moreover, since ATP synthase ligands are potentially useful drugs in cancer 
therapy, pharmacophore models were constructed to pave the way for novel 
inhibitor designs. 
Keywords:  pharmacophore; quantitative structure-activity relationships; ATP   
synthase ligands 
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1. Introduction 
Previously, new drugs were found only by a trial and error approach. Potentially, anything deemed 
to be of medicinal value in a specific disease could be tested on patients to determine its efficacy [1]. 
As the science of chemistry advanced, researchers started to purify the active compounds in herbal 
preparations known to have medicinal properties, and deduce the structures of these active 
compounds [1]. The science of drug design progressed further with advances in molecular biology and 
biochemistry, which elaborated the concepts of genes and ligand-receptor relationships [2]. The most 
important breakthrough came with the emergence of genomics, proteomics and the development of 
bioinformatics and chemoinformatics. The concept and techniques of large-scale screening, which can 
be applied to identify disease-related genes and proteins, were first introduced in genomics and 
proteomics [3], as bioinformatics [4] and chemoinformatics [5] further sought to uncover methods for 
large-scale data processing and in silico experimentation. 
The goal of drug design is to select a target in the etiology of a disease and find one or more 
compounds which interacts with that target [6], and in doing so activates or blocks the given target [2]. 
Ideally, the resultant changes in target protein activity will go on to influence a series of reactions and 
lead to an improvement in the clinical outcome [7]. 
After a suitable target has been identified, the drug design process can begin. If reliable information 
on the 3-D structure and active sites of the target protein can be obtained from X-ray crystallography, 
nuclear magnetic resonance, or 3-D structure databases, and incorporated into a computer model, 
compounds binding to the target can be designed [8]. This approach is known as “structure-based drug 
design”. Frequently used techniques in this approach are docking and molecular dynamics 
simulation  [9]. Potent ligands can be found by screening a molecule database with docking 
software [10]. Molecular dynamics simulation can be useful to ascertain not only how a molecule 
interacts with the target protein, but also to determine some other properties of the molecule itself, 
such as membrane permeability [11,12]. 
In some cases, usually in which data pertaining to the 3-D structure of a target protein are not 
available, drug design can instead be based on processes using the known ligands of a target protein as 
the starting point. This approach is known as “ligand-based drug design”. Molecular similarity 
approaches, quantitative structure-activity relationships (QSAR) and pharmacophore models are 
frequently used methods in the ligand-based drug design process [13]. By using the molecular 
fingerprints of known ligands, databases can be screened to find molecules with similar 
fingerprints [14]. Common structural features of ligands can be found using pharmacophore modeling, 
which can then be used to screen for molecules with these features [15]. To predict the activity of a 
novel molecule, models can be built with QSAR [16]. While a pharmacophore model may only 
indicate the activity-conferring features of an active ligand, the relationship between chemical or 
physical properties of ligand and biological activity can be more fully explored using the QSAR model. 
This review will focus on QSAR and pharmacophore modeling and elaborate on their fundamental 
concepts, workflows for building models, and their applications. Pharmacophore models of the ATP 
synthase beta subunit-binding ligands selected from existing literature are also discussed here as   
an illustration. Int. J. Mol. Sci. 2011, 12                 
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2. Pharmacophore 
The term “pharmacophore” was first defined by Ehrlich as: “a molecular framework that carries the 
essential features responsible for a drug’s biological activity” [17]. It follows from this definition that a 
pharmacophore defines the necessary features that an active ligand should possess. Generally, feature 
type, position, and direction of an active ligand would be encoded into a pharmacophore model, along 
with possible steric constraints of the active compound [18]. 
A 3-D pharmacophore would reflect how key amino acids are positioned in the active site of a 
target protein [19]. For example, a key amino acid residue which acts as a hydrogen-bond acceptor 
should be in the vicinity of a hydrogen-bond donor feature in the pharmacophore model, accounting, in 
part, for the protein-ligand interaction. Once a ligand binds to the target protein in the correct 
conformation and interacts with key amino acid residues, the conformation of the protein may be 
changed or become locked, depending on the mechanism of ligand-protein interaction [2]. 
A pharmacophore model can be generated from a set of known ligands. However, data pertaining to 
3-D protein structure or protein-ligand complexes combined with information on active sites can also 
be used to model a pharmacophore [20]. By studying the binding site, possible interactions between 
the active compound and the protein can be inferred, and pharmacophore models can be built from 
data on target protein structure. 
Pharmacophore models are widely used to elicit specific inhibitors of disease-related proteins, 
including G-protein coupled receptors, enzymes, and ion channels [21]. It is also used with other drug 
discovery methods, as has been described in the “Applications” subsection. 
2.1. Construction of a Pharmacophore Model 
The detailed workflow of pharmacophore model construction will depend on the software package 
one uses. However, the general procedure can be summarized as follows [18]: Ligands are first 
selected and their usability confirmed. If a 3-D pharmacophore model is being constructed, sets of 
conformers, or conformations of a ligand, are generated. According to IUPAC, conformations are 
defined as the spatial arrangement of the atoms affording distinction between stereoisomers [22]. The 
conformers, or the 2-D structures if a 2-D pharmacophore model, which define only the required atom 
types and their connectivity [23] being built, are then used to determine features common to the 
selected ligands required to build the pharmacophore model. In general, more than one pharmacophore 
model is generated from the selected ligand set. Ranking and validating the model is the final step in 
pharmacophore model construction. Most pharmacophore modelers conduct the whole workflow with 
the help of a chemoinformatics software package, since all the required tools are found in this type  
of package. 
The first step in pharmacophore modeling is to assemble an active compound set, usually from 
literature searches and molecular database querying. The researchers can use all databases available, 
including commercial, in-house, or public databases. A consistent threshold to define a compound 
active should be applied while searching active compounds from multiple sources. Activity levels of 
the compounds are not necessary if it is not necessary to build a pharmacophore-based QSAR model 
subsequently. After a set of molecules is selected, ensuring that all selected molecules exert their 
biological effects via the same mechanism is another important issue which should be considered Int. J. Mol. Sci. 2011, 12                 
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before continuing pharmacophore model construction [18]. The structures of the molecules should be 
confirmed after checking their biological mechanism. In some cases, the chemical structures are 
manually sketched in a software package, which is an error-prone process. Even if the chemical 
information comes from a well-known database, a modeler should be cautious since such data is not 
always accurate. The pharmacophore model describes the interaction between the active site of a target 
protein and a ligand [19]; therefore the use of data pertaining to different active sites on the target 
would produce an entirely spurious pharmacophore model. Even if the pharmacophore elucidation 
software could generate results from such input, the resulting model would be meaningless. 
If a representative 3-D pharmacophore model is to be built, a reasonable conformation set should be 
generated prior to alignment. The quality of the output set of the conformation generator,   
including such considerations as coverage and energy of the conformers, impacts on the quality of  
generated model [24]. 
The next step is to build the pharmacophore model from the common features found among the 
ligands. To find common features, the ligands are aligned, or superimposed with the assistance either 
of a conformer database of the relevant ligands or of an on-the-fly conformation generator [20]. After 
the alignment step is completed, the pharmacophore models are generated by a pharmacophore 
elucidation algorithm. More than one output model can often be obtained from this procedure, and 
selecting the best ones from the results is an important task [25]. This is usually assisted by the scoring 
function contained within the pharmacophore-building software. Generally, the model with the highest 
score is the most representative member of the output model set. 
The best models are subjected to the validation process. If the receptor-ligand binding mechanism is 
clearly understood, this information can be utilized to validate the pharmacophore model, since the 
pharmacophore model can sometimes reflect the 3-D structure of the binding site, as previously 
stated [19]. If a pharmacophore model conflicts with previously established binding mechanisms, the 
modeler should consider rejecting it, or try to account for the discrepancies between documented 
binding data and the newly built pharmacophore model. A pharmacophore model should always be 
validated by ligands that are not included in the training set despite whether previously known binding 
mechanisms exist or not. If a pharmacophore model cannot pass this validation, it should be rejected 
and the modeling process reviewed. 
2.2. Applications of Pharmacophore Models 
Pharmacophore models are often employed in virtual screening processes. For example, Mustata et al. 
discovered novel Myc-Max heterodimer disruptors [26] by using a pharmacophore model generated 
using known disruptors. In this study, the authors performed the virtual screening with the 
pharmacophore model after it was validated by using a non-training molecule set. Bioassays were then 
conducted to check the potency of the screened molecules. 
Another example of the use of pharmacophore models in drug discovery is the identification of 
novel PPARγ partial agonists by Petersen et al. [27]. The authors found that full agonists at the PPARγ 
had unwanted side effects, as previous research had indicated [28], so it was a priority to find new 
compounds which could act as partial agonists at PPARγ. A pharmacophore model was built from a 
collection of known partial agonists, and it was validated with a newly discovered partial agonist. Int. J. Mol. Sci. 2011, 12                 
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After inspecting the hit list generated by virtual screening with the pharmacophore model, methyl 
oleanonate, a derivative of oleanonic acid, was selected because oleanonic acid can be easily obtained. 
Purification and bioassay were conducted after its potential to act as a partial agonist was confirmed by  
docking simulation. 
In addition to the uses described above, pharmacophore models can be used as filters to reduce false 
positives, either during preprocessing of a molecular database before submission to another virtual 
screening procedure [29], or to filter the results of other virtual screening processes [30]. 
An example of the use of a pharmacophore model as a preprocessor can be found in the Chk-1 
kinase study by Lyne et al. [29]. In this research, the authors preprocessed the molecule database using 
molecular weight and rotational bond limits and a user-defined 3-D pharmacophore model. The 
remaining ligands were then docked into the binding site of the kinase and scored by a scheme defined 
by the authors. The potencies of the resulting molecules were tested in a Chk-1 kinase assay, an 
in vitro bioassay protocol. 
Pharmacophore models can also be used to process the output of virtual screening protocols, as 
shown in the research of Peach et al. [30]. Although the pharmacophore model in this study was 
generated manually from receptor binding site data obtained from literature and 3-D structure database 
searches, it aptly demonstrated the way in which a pharmacophore model can be used as a filter. In this 
research, the authors supported the validity of their method with three examples. First, the 
pharmacophore model was constructed from 3-D receptor-ligand complexes and from literature data. 
A docking simulation was performed, with all output tested by the pharmacophore models. During this 
process, a molecule is only recognized as a hit if it matches with all generated pharmacophore models. 
This approach performed better than scoring functions provided by the docking algorithms used here. 
The value of this approach, in contrast to the pharmacophore preprocessor method, is that the   
time-consuming docking simulation does not need to be repeated if the pharmacophore model is 
subsequently changed [30]. 
3. QSAR 
QSAR, which stands for “quantitative structure-activity relationships”, is a method that relates 
chemical structure to biological or chemical activity using mathematical models [31]. If the activity of 
a set of ligands can be determined, a model can be constructed to describe this relationship. Unlike a 
pharmacophore model, which encodes only the essential features of an active ligand, the QSAR model 
allows one to determine the effect of a certain property on the activity of a molecule. For example, the 
QSAR model may reveal a property to have a highly negative, or alternatively a weak positive effect 
on ligand activity. Such information is not available using a pharmacophore model. 
Quantifying the structure and activity of a ligand is important in the modeling process. Structure 
quantification is not a trivial problem, since a structure cannot be represented by a mere value. Instead, 
a set of properties, usually known as the “descriptors”, is computed from the structure and used to 
quantify it. By using structural descriptors as independent variables and activity as a dependent 
variable, a model can be built to describe the relationship between the two [32]. 
After a QSAR model is built and validated, it can predict the biological activity of novel molecules 
from their structural properties. A QSAR model can also screen potentially active molecules from a Int. J. Mol. Sci. 2011, 12                 
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database, as described in the section on applications of the technique. Because the QSAR model can 
incorporate a wide range of different variables, be it physical, chemical or biological, it can also be 
utilized in industries apart from drug design [33], such as toxicology [34], food chemistry [35], and 
other fields. 
3.1. Building a QSAR Model 
The process of constructing a QSAR model can be summarized as follows [36]: First, ligands and 
their activities are collected. Descriptors are calculated and selected before a mathematical modeling 
method is chosen and the ligand data are then used to construct the QSAR models. After the models 
are completed, they are tested by internal and external validation procedures. Only then can a QSAR 
model be used in any practical applications, such as predicting the activity of a novel compound. 
As is the case when building a pharmacophore model, the active ligand set must be gathered from 
molecular databases or from literature searches before QSAR modeling begins. The process requires 
not only the collection of ligand structures but also of their activities. Generally, IC50s (half maximal 
inhibitory concentration) [37], EC50s (half maximal effective concentration) [38], and Ki values 
(inhibition constant) [39] are commonly used to quantify drug activity. However, the quantification of 
ligand activity as used in QSAR is not limited to pharmacokinetic parameters. Other activity indexes 
can also be incorporated into model depending on the phenomena one wishes to predict. For example, 
Chen  et al. used corneal permeability coefficient as the activity index to construct a model that 
predicted the efficiency of drug delivery in various eye drop medications [40]. In addition to structure 
verification as described in the section on pharmacophore model construction, ligand activity data 
should also be checked. All activity data should come from the same experimental procedure or assay, 
and it is preferable if the data comes from the same laboratory, and even the same researcher [32]. 
Before a QSAR model can be built, ligand structure descriptors should be ascertained or calculated. 
Some descriptors obtained directly from data sources or calculated using simple arithmetic operations 
take into account the specific number of atoms, molecular chain length, molecular mass, .etc. However, 
other descriptors may require complex computation, for example pharmacophore-based 
descriptors [41], molecular field descriptors, which are derived from the interaction of probes and 
molecules and used in CoMFA and CoMSIA [42,43], and spectral descriptors derived from the IR 
spectrum of the ligand [44]. It is important that the descriptors are related to the biological or chemical 
activity which the model will be used to predict [45]. In other words, if a descriptor is not related to 
activity, one should avoid incorporating the descriptor into the modeling process. 
After the activity index (the dependent variable) and descriptors (the independent variables) are 
prepared for each ligand, a variable selection method and a modeling method can be selected, and a 
model is built. The selection process should avoid redundant descriptors, and then a model is built 
using the selected descriptors [46]. If two descriptors represent a similar biological or chemical 
parameter, one of them should be disregarded. In order to select descriptors, genetic algorithms [47,48], 
principle component analysis [49], artificial neural networks [50] and k-nearest neighbor [51] 
approaches can all be used. If a linear model is assumed, some conventional statistical methods, such 
as the partial least squares method and multiple linear regression [16] can be used. If a nonlinear Int. J. Mol. Sci. 2011, 12                 
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model is preferred on the other hand, machine learning methods like artificial neural networks [52] or 
support vector machines [53] can be applied. 
The main differences among the frequently used QSAR algorithms reside in their means of 
descriptor generation. For example, most QSAR algorithms, like CoMFA [42], CoMSIA [43], 
CoMMA [54], and HypoGen [55], use similar linear statistical models to explore the relationship 
between activity and descriptors, which are calculated by different processes. In CoMFA and CoMSIA, 
pre-aligned molecules are put onto a grid, or lattice. The descriptors are calculated by the interaction of 
the molecule and a probe is placed at each intersection of the lattice. The differences between CoMFA 
and CoMSIA are in the use of different probes and interaction-calculating functions. In CoMFA, only 
probes representing steric and electrostatic interactions can be used. In CoMSIA, probes representing 
hydrophobic and hydrogen bond interactions, in addition to CoMFA probes may be selected. In 
addition, CoMSIA uses a Gaussian-type function for calculating prober-molecule interaction. By using 
such a smooth function, the result value is more reasonable than the function used in CoMFA, and 
defining a cut-off limit to remove invalid values is no longer required. The descriptors used in 
CoMMA are generated by computing the spatial moments of the molecules. On the other hand, the fit 
value is the only descriptor source employed in the HypoGen model generation process. The fit value 
describes the goodness of alignment between a ligand and a pharmacophore model and is obtained 
from a pharmacophore model generated and optimized using known structure and activity data.  
The model must then be validated before it can be used to predict activity. There are some popular 
methods used to validate a QSAR model [56], including internal validation approaches (such as the 
“leave-one-out” or “leave-n-out” cross validation methods [57]), and external validation approaches. 
In cross validation, one (leave-one-out) or more (leave-n-out) ligand of the training set is excluded. 
The excluded data is predicted by the model constructed with reduced training set data. These steps are 
repeated until all data has been excluded and predicted, and the power of a model is determined by the 
accuracy of prediction [57]. External validation is a widely used method, and is considered important 
in the QSAR building pipeline [58]. In external validation, the capability of the model is tested using 
data which is not included in the training set, in contrast to internal validation, which utilizes data 
taken from the training set to validate the model [59]. In most of the studies, both internal and external 
validations are performed to ensure the reliability of the model (see following subsection 
“Applications of QSAR”). After the model has passed these strict validation tests, it can be used to 
predict the activity of novel molecules. 
3.2. Applications of QSAR 
As previously discussed, QSAR is widely used when a predictive model is required. In the work of 
De Melo, a PC (principle component) -SAR model was developed to predict if a molecule is active, 
and a PLS (partial least squares) -QSAR model was developed to predict the degree of activity of an 
active compound [37]. The author validated the QSAR model employing both internal (the “leave-n-
out” method) and external validation approaches. From the two models, the author found several 
important chemical properties that contributed to the activity of the molecule. 
Another example of this type of method is the QSAR analysis of CCR2 inhibitors, by   
Saghaie et al. [60]. CCR2 is a chemokine G-protein coupled receptor important in certain inflammatory Int. J. Mol. Sci. 2011, 12                 
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disorders. In this study, the authors used a genetic algorithm to select key descriptors, and then built 
the QSAR model using a stepwise multiple linear regression approach. The model was validated in 
accordance with the literature [58] both internally (using the “leave-one-out” and “leave-five-out” 
methods) and externally. However, no bioassay data were given in this study. 
In a study conducted by Obiol-Pardo et al. [61], two QSAR models were incorporated into a 
multiscale simulation system which was designed to predict drug-induced cardiotoxicity by the 
interactions of drug molecules with two potassium channels, hERG and KCNQ1. First, a docking 
simulation was executed to determine the active conformation of the ligands. QSAR models, which 
used field-based descriptors, were constructed for each potassium channel by the partial least squares 
method. The QSAR models were validated internally (with the “leave-one-out” method) and externally 
after model construction. The IC50 values for drugs acting on hERG and KCNQ1 predicted by the 
QSAR models were used as the input for two previously studied models, which could predict action 
potential duration and pseudo-ECG (for extraction of the QT interval) respectively. Drug-induced 
arrhythmia was reported to affect the QT interval and action potential duration. By employing this 
multiscale model, the cardiotoxicity of a novel drug was assessed without using any in vitro or   
in vivo assays. 
4. Pharmacophore Models of ATP Synthase Beta Subunit-Binding Ligands 
In our previous research, ATP synthase was discovered to be over-expressed on the cell membranes 
of a breast cancer cell line [62]. Aurovertin B, which binds to the beta subunits of ATP synthase, was 
also found to be a drug of potential value in the targeted therapy of breast cancer [62]. However, 
because of the structural complexity of aurovertin B, which makes it a difficult compound to 
synthesize, it has become important to design a new drug to target ATP synthase for use in cancer 
research. To achieve this goal, the common backbone, a substructure bearing required functional 
groups of the ligands, should be deduced. Although a shared backbone might be found by aligning all 
the molecules, important groups might not be inferred from such an alignment. The backbone and 
important functional groups are both vital to the design of a new inhibitor. For this reason, a 
pharmacophore model was built to determine common functional groups. After relevant functional 
groups are identified, shared backbone structure can be deduced from original structure by removing 
branches which contain no necessary functional groups if the molecules can be soundly aligned to the 
pharmacophore and each other. 
Data pertaining to known ligands of the ATP synthase beta subunit were retrieved from the 
PubChem [63] database by querying with their names found on the literature [64], with the exception 
of the peptide enterostatin and bathophenanthroline-metal chelates (see Figure 1). These two 
molecules were sketched manually and checked carefully using the Discovery Studio package. The 
ligands were separated into two groups, Group 1 (G1) and Group 2 (G2), according to their binding 
site location as described in the literature [64]. The compounds of G2 are known to bind to the same 
site on the ATP synthase beta subunit, whereas the G1 molecules are known to bind to the ATP 
synthase beta subunit, although the precise location of their binding site(s) was not clear: molecules in 
this group may bind to different location of ATP synthase beta subunit. Because reliable activity data Int. J. Mol. Sci. 2011, 12                 
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for some molecules could not be obtained, we decided to generate a common feature pharmacophore 
model instead of a 3-D QSAR pharmacophore model. 
Figure 1. ATP synthase beta subunit ligands used in the pharmacophore modeling   
process. Structures, names, and PubChem Compound database IDs are listed.   
* Bathophenanthroline-metal chelate was constructed from bathophenanthroline and 
ferrous iron in the ratios 1:1 and 3:1, but a conformer could not be generated (as stated in 
the following paragraph). Since the conformer generation of the chelate failed, it was not 
included in the training set when building the pharmacophore model. 
 
Common feature pharmacophore models for each group were constructed using the HipHop 
algorithm [65] after the conformers were generated using the “BEST” algorithm [66]. All the 
algorithms are included in the Discovery Studio package (version 2.1) from Accelrys. 
The best pharmacophore model of the G1 set, as determined by the ranking score generated by the 
HipHop algorithm, is shown in Figure 2. As described in previous discussions, since the molecules in 
G1 did not share a common binding site on ATP synthase beta subunit, they should not be used as 
training sets when building pharmacophore models. However, we would like to demonstrate that 
pharmacophore models can be built by pharmacophore elucidating software even if the training set 
cannot meet the criteria discussed above. Bathophenanthroline-metal chelate is not present in the 
alignment of the final result. The conformation generator could not generate conformers for the chelate 
mixture, thus the chelate was automatically excluded from the input training set. Despite the fact that Int. J. Mol. Sci. 2011, 12                 
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G1 molecules are not known to have a common binding site, a pharmacophore model could be 
generated by HipHop, which was an unexpected finding. The ligands might share the same binding 
site on the ATP synthase beta subunit because they share some chemical features, as indicated by the 
generated pharmacophore model; further structural studies of ATP synthase are required to reveal the 
binding site(s) of these ligands. Nevertheless, researchers need to shoulder the responsibility of 
checking the binding characteristics of ligands, as described in the previous section; otherwise a 
pharmacophore model which stands a high chance of being meaningless may be generated, as 
demonstrated by the pharmacophore model presented here. 
Figure 2. The  pharmacophore model generated from the G1 molecule set. Left panel: 
pharmacophore model and aligned ligands; Right panel: pharmacophore model only; 
Green indicates a hydrogen bond acceptor feature; Cyan, a hydrophobic feature. The direction 
of the hydrogen bond acceptor (shown with arrows) indicated an optimal alignment of 
the features. 
 
The best pharmacophore model of the G2 set, as determined by the ranking score generated by the 
HipHop algorithm, is shown in Figure 3. As predicted, the G2 molecules were aligned better than the 
G1 molecules. Three similar molecules, aurovertin B, aurovertin D, and asteltoxin, were in this group. 
In addition, resveratrol and piceatannol are two very similar molecules. However, it can be clearly 
seen that the G2 molecules can be separated into two sets by putting resveratrol and piceatannol 
together into one group, and putting the remaining molecules into the other. Although this action might 
affect the generated pharmacophore model, the results bear some resemblance to the results of the 
docking simulation performed in our previous study [62]: The hydrogen bond donor feature can be 
mapped to the Lue342 residue, and the hydrogen bond acceptor features can be mapped to the Lys382, 
Arg412 residues of the ATP synthase beta subunit. These observations were not beyond what we 
expected to achieve, since a 3-D pharmacophore model can reflect the arrangement of the key residues 
of the binding site [19]. However, after careful inspection, the pharmacophore model feature vectors 
indicating the direction of the hydrogen bonds were different from those of the previous docking 
simulation, and the interaction poses were different as well. In addition, the fit value (not shown) of 
aurovertin B was not as high as expected. As in our previous research, the activity of aurovertin B was 
significantly higher than resveratrol and piceatannol [62]. Furthermore, accurate alignment of the two Int. J. Mol. Sci. 2011, 12                 
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aurovertins and asteltoxin was expected because of their structural similarity but was not observed in 
our results. Although this pharmacophore model can reflect the binding mode discovered in our 
previous research, this model was not validated experimentally. We present the model here for 
demonstration of the pharmacophore modeling process. One should conduct validation before using 
this pharmacophore model in their research. 
Figure 3. The pharmacophore model generated from the G2 molecules. Left panel: the 
pharmacophore model and the aligned ligands; Right panel: pharmacophore model only; 
Green indicates a hydrogen bond acceptor feature; Purple, a hydrogen bond donor feature. 
The direction of the hydrogen bond acceptor and hydrogen bond donor (shown with arrows) 
indicates optimal alignment of the features. 
 
5. Conclusions 
QSAR and pharmacophore models are two widely used techniques in the rational drug design 
process. In this review, the basics of the pharmacophore and QSAR techniques were introduced, and 
the basic modeling processes for both methods, along with some possible pitfalls, were discussed. 
After the fundamental concepts of the two methods were covered, some studies using each technique 
were explored. Previously unpublished pharmacophore models generated from a range of ATP 
synthase beta subunit ligands were also used to demonstrate the workflow of a pharmacophore 
modeling process. It is important to know the basics and pitfalls of these computer-aided drug design 
techniques. Knowledge of such techniques can aid researchers in selecting the best technique for their 
given objectives. However, results may still be prone to error, especially when there is disagreement 
between input and assumptions of the selected techniques. It is also important to bear in mind that 
better results may be yielded by combining QSAR and pharmacophore models with other drug design 
methods, as shown in the example sections of this review. Int. J. Mol. Sci. 2011, 12                 
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